Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Debt and delayed care forecast for some who lose insurance under tax and spending law

    2. August 2025

    What to Know About the Condition

    2. August 2025

    Vicarious Surgical names Stephen From as next CEO

    2. August 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»MAGENTIQ EYE Secures Funding to Advance AI-Powered Gastroenterology Diagnostics
    News

    MAGENTIQ EYE Secures Funding to Advance AI-Powered Gastroenterology Diagnostics

    HealthradarBy Healthradar1. August 2025Keine Kommentare2 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    MAGENTIQ EYE Secures Funding to Advance AI-Powered Gastroenterology Diagnostics
    Share
    Facebook Twitter LinkedIn Pinterest Email


    MAGENTIQ EYE Secures Funding to Advance AI-Powered Gastroenterology Diagnostics
    Founded in 2014, MAGENTIQ-EYE offers a groundbreaking AI-aided colonoscopy solution that offers one of the best performances known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy, and saving more and more lives.

    What You Should Know: 

    – MAGENTIQ EYE LTD., an innovator in AI-powered gastroenterology decision-support software, announced completion of its Series A funding round led by aMoon, with participation from existing investors Norgine Ventures BV (Netherlands), Nina Capital (EU & USA), Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA).

    The proceeds from the funding round will support the continued development and expansion of MAGENTIQ EYE’s diagnostic tools, in addition to driving commercial growth in the USA, Europe, and globally. The company plans to use direct sales and partnerships with industry leaders to achieve this growth.

    Enhancing Polyp Detection and Clinical Insights

    MAGENTIQ EYE’s FDA- and CE-approved software, MAGENTIQ-COLO™, is designed to enhance polyp detection and analysis capabilities during colonoscopies. The software significantly improves adenoma detection rates and offers real-time insights. The CE-approved version of MAGENTIQ-COLO also includes polyp-size category and type estimation, as well as advanced AI-generated reports.

    According to Roy Wiesner, a partner at aMoon who will be joining the board of directors, MAGENTIQ’s solution stands out as the most accurate on the market, offering the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications.

    The company is currently in clinical trials for diagnostic tools targeting specialized diseases in the lower and upper gastrointestinal tract, such as ulcerative colitis, early dysplasia in Barrett’s esophagus, and gastric intestinal metaplasia. It is also developing automated quality indicators for GI procedures.

    “This investment round marks a major milestone for MAGENTIQ EYE. We are thrilled to welcome aMoon and Roy Wiesner to our journey,” said Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE. “With aMoon’s support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the U.S. and Europe, and bring our advanced diagnostic tools to more physicians and patients around the world.”



    Source link

    Advance AIPowered Artificial Intelligence Diagnostics Eye Funding Gastroenterology MAGENTIQ Secures
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleStryker lowers expected tariff impact to $175M
    Next Article iRhythm, Lucem Health Partner to Detect Arrhythmia with AI
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    Vicarious Surgical names Stephen From as next CEO

    2. August 2025
    Health

    iRhythm, Lucem Health Partner to Detect Arrhythmia with AI

    1. August 2025
    News

    Stryker lowers expected tariff impact to $175M

    1. August 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20257 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20257 Views

    Whoop wants everyone to give a whoop about the new Whoop 5.0

    1. Juni 20254 Views

    How nanoplastics may be impacting our long-term health

    27. Juli 20253 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    New surgeon general nominee cofounded a16z backed health app with DOGE operative

    1. Juni 20257 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20257 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.